News
Latest press releases – plus an archive of press releases, thus recording milestones and key facts in Sunstone’s history.
Patent for Oncoral approved in Japan
Ascelia Pharma AB (publ) (ticker: ACE) (“Ascelia”) today announced that the patent application for Oncoral has been approved in Japan. The approval in Japan adds to the already obtained patents in the US and a selected number of countries in Europe and China. The...
Susanne Rydberg utses till ny VD för Arcoma AB
Styrelsen i Arcoma har utsett Susanne Rydberg till ny Verkställande Direktör. Susanne Rydberg har lång erfarenhet från ledande positioner, senast nu som VD för Eurofins BioPharma Product Testing Sweden AB och dessförinnan som verksamhetschef för Lindes Nordeuropeiska...
Sunstone announce new investment in immuno-oncology company STipe Therapeutics
Sunstone Life Science Ventures today announce it has invested in new portfolio company Stipe Therapeutics ApS (“STipe”), an immuno-oncology company dedicated to developing novel cancer therapeutics based on its first class drugs modulating the STING pathway.
Zealand Pharma achieves primary and all key secondary endpoints in pediatric Phase 3 trial with dasiglucagon for severe hypoglycemia
Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces positive results in the pediatric Phase 3 trial with dasiglucagon for severe hypoglycemia...
Sunstone makes €5 million investment into Finnish women’s health company Forendo Pharma to finance clinical studies in endometriosis
Sunstone Life Science Ventures today announced its first investment out of its Life Science Ventures Fund IV into Forendo Pharma, a Finnish clinical stage drug development company focusing on novel treatments in women’s health. The investment is designated to finance...
Sunstone makes a non-revocable commitment to sell all shares in Nuevolution at a price of SEK 32.5 per share to Amgen, corresponding to SEK 332 million
Sunstone today announced that its Life Science Ventures Fund I has made a non-revocable commitment to sell all shares in Nuevolution AB at a price of SEK 32.5 per share. Nuevolution has been part of Sunstone’s portfolio since 2007 and Sunstone has played an active...